Gene Dysregulation and Islet Changes in PDAC-Associated Type 3c Diabetes

Area of Science:

• Oncology
• Endocrinology
• Genomics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer frequently linked to new-onset diabetes, particularly type 3c diabetes.
• The precise relationship and underlying mechanisms connecting PDAC and diabetes remain unclear, necessitating further investigation.

Purpose of the Study:

• To determine if PDAC-associated diabetes constitutes a distinct subtype by integrating transcriptomic and histological analyses.
• To compare gene expression profiles and immune cell populations between PDAC patients with and without diabetes.

Main Methods:

• Analysis of whole-tumour RNA sequencing data from The Cancer Genome Atlas (TCGA).
• Utilized Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) for immune cell deconvolution.
• Performed histopathological evaluations of pancreatic tissues, focusing on fibrosis and islet morphology.

Main Results:

• Histological analysis revealed perivascular fibrosis and islet basement membrane thickening in both PDAC groups.
• Transcriptomic data showed downregulation of insulin (INS) and glucagon (GCG) genes in PDAC-associated diabetes, aligning with a type 3c diabetes phenotype.
• No significant differential expression of key immune checkpoint genes (PDCD1, CTLA4, PD-L1) was observed, refuting a distinct immunogenic signature.

Conclusions:

• PDAC-associated diabetes appears to result from neoplastic alterations affecting islet physiology, rather than immune-mediated mechanisms.
• Reduced expression of endocrine markers suggests PDAC-driven beta-cell dysfunction may serve as an early malignancy indicator.
• Further research into novel therapeutic strategies targeting tumor-islet interactions is warranted, given PDAC's limited response to PD-L1 inhibitors.